offline
J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short
Johnson & Johnson’s JNJ fourth-quarter 2019 earnings came in at $1.88 per share, which beat the Zacks Consensus Estimate of $1.86. Earnings, however, declined 4.6% from the year-ago period.
Adjusted earnings exclude after-tax intangible amortization expense and some special items. Including these items, J&J reported fourth-quarter earnings of $1.50 per share, up 33.9% from the year-ago quarter.
Sales of the drug and consumer products giant came in at $20.75 billion, which missed the Zacks Consensus Estimate of $20.79 billion. Sales rose 1.7% from the year-ago quarter, reflecting an operational increase of 2.6%, which offset an unfavorable currency impact of 0.9%.
...
https://finance.yahoo.com/news/j-js-jnj-...03101.html
![[Bild: JNJc1dl1508.png]](https://finviz.com/publish/012320/JNJc1dl1508.png)
Johnson & Johnson’s JNJ fourth-quarter 2019 earnings came in at $1.88 per share, which beat the Zacks Consensus Estimate of $1.86. Earnings, however, declined 4.6% from the year-ago period.
Adjusted earnings exclude after-tax intangible amortization expense and some special items. Including these items, J&J reported fourth-quarter earnings of $1.50 per share, up 33.9% from the year-ago quarter.
Sales of the drug and consumer products giant came in at $20.75 billion, which missed the Zacks Consensus Estimate of $20.79 billion. Sales rose 1.7% from the year-ago quarter, reflecting an operational increase of 2.6%, which offset an unfavorable currency impact of 0.9%.
...
https://finance.yahoo.com/news/j-js-jnj-...03101.html
__________________
